Forxiga 5 mg 28 tablets

Trade name:

Forsiga

Forxiga

Composition

Each tablet contains:

dapagliflozin 5 mg

Auxiliary components:

microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, magnesium stearate.

Properties

Dapagliflozin is a potent (inhibition constant (Ki) 0.55 nM), selective reversible inhibitor of the sodium glucose cotransporter type 2 (SGLT2).

Inhibition of SGLT2 by dapagliflozin causes a decrease in the reabsorption of glucose from the glomerular filtrate in the proximal renal tubules with a concomitant decrease in sodium reabsorption, leading to excretion of glucose by the kidneys and osmotic diuresis. Thus, dapagliflozin increases sodium delivery to the distal tubules, which is believed to enhance tubular-glomerular feedback and decrease intraglomerular pressure. Secondary effects of SGLT2 inhibition with dapagliflozin also include a moderate decrease in blood pressure, weight loss, and an increase in hematocrit.

Indications

Type 2 diabetes mellitus in adult patients in addition to diet and exercise to improve glycemic control as:

— monotherapy, when the use of metformin is impossible due to intolerance;

— combined therapy with metformin, sulfonylurea derivatives (including in combination with metformin), thiazolidinediones.

Contraindications

-increased individual sensitivity to any component of the drug;

— type 1 diabetes mellitus;

diabetic ketoacidosis;

Side effects

Infectious and parasitic diseases: often — vulvovaginitis, balanitis and related infections of the genital organs, urinary tract infections;

From the side of metabolism: very often — hypoglycemia (when used in combination with a sulfonylurea derivative or insulin);

From the nervous system: often — dizziness.